Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8.1 years median follow-up

Regan, Meredith; Neven, Patrick; Giobbie-Hurder, Anita; Goldhirsch, Aron; Ejlertsen, Bent; Mauriac, Louis; Forbes, John; Smith, Ian; Lang, Istvan; Wardley, Andrew; Rabaglio, Manuela; Price, Karen; Gelber, Richard; Coates, Alan; Thuerlimann, Beat

doi:10.1016/s1470-2045(11)70270-4

Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8.1 years median follow-up

Atıf İçin Kopyala

Regan M. M., Neven P., Giobbie-Hurder A., Goldhirsch A., Ejlertsen B., Mauriac L., ...Daha Fazla

LANCET ONCOLOGY, cilt.12, sa.12, ss.1101-1108, 2011 (SCI-Expanded)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 12 Sayı: 12
Basım Tarihi: 2011
Doi Numarası: 10.1016/s1470-2045(11)70270-4
Dergi Adı: LANCET ONCOLOGY
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Sayfa Sayıları: ss.1101-1108
İstanbul Üniversitesi Adresli: Hayır

Özet

Background Postmenopausal women with hormone receptor-positive early breast cancer have persistent, long-term risk of breast-cancer recurrence and death. Therefore, trials assessing endocrine therapies for this patient population need extended follow-up. We present an update of efficacy outcomes in the Breast International Group (BIG) 1-98 study at 8.1 years median follow-up.